72.45Open72.45Pre Close0 Volume2 Open Interest160.00Strike Price0.00Turnover0.00%IV-2.32%PremiumJan 17, 2025Expiry Date77.98Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.05Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet